Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-03-01
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004171
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027924
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 744
- Registration Number
- NCT00002868
- Locations
- 🇬🇧
Royal Infirmary, Glasgow, Scotland, United Kingdom
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005986
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 31
- Registration Number
- NCT00077116
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇧🇪AZ Sint-Jan, Brugge, Belgium
🇧🇪H. Hartziekenhuis - Roeselaere., Roeselare, Belgium
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
- Conditions
- First Posted Date
- 2003-12-02
- Last Posted Date
- 2015-07-20
- Target Recruit Count
- 50
- Registration Number
- NCT00003414
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2009-02-09
- Target Recruit Count
- 207
- Registration Number
- NCT00002989
- Locations
- 🇮🇹
Ospedale San Eugenio, Rome, Italy
🇧🇪Institut Jules Bordet, Brussels (Bruxelles), Belgium
🇩🇪Eberhard Karls Universitaet, Tuebingen, Germany
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2020-06-30
- Target Recruit Count
- 6
- Registration Number
- NCT00003060
- Locations
- 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Columbia University
- Registration Number
- NCT00002761
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00006367
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Illinois College of Medicine, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.